dc.contributor.author | Akşit, Dilek | |
dc.contributor.author | Yalınkılıç, Hande Sultan | |
dc.contributor.author | Sekkin, Selim | |
dc.contributor.author | Boyacıoğlu, Murat | |
dc.contributor.author | Çırak, Veli Yilgor | |
dc.contributor.author | Ayaz, Erol | |
dc.contributor.author | Gökbulut, Cengiz | |
dc.date.accessioned | 2019-10-17T10:28:11Z | |
dc.date.available | 2019-10-17T10:28:11Z | |
dc.date.issued | 2015 | en_US |
dc.identifier.uri | https://doi.org/10.1186/s12917-015-0442-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12462/8083 | |
dc.description | Akşit, Dilek (Balikesir Author) | en_US |
dc.description.abstract | Background: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMC | en_US |
dc.relation.isversionof | 10.1186/s12917-015-0442-5 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Benzimidazoles | en_US |
dc.subject | Albendazole | en_US |
dc.subject | Albendazole Sulfoxide | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | Enantiomers | en_US |
dc.subject | Sheep | en_US |
dc.subject | Goat | en_US |
dc.title | Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats | en_US |
dc.type | article | en_US |
dc.relation.journal | BMC Veterinary Research | en_US |
dc.contributor.department | Veteriner Fakültesi | en_US |
dc.contributor.authorID | 0000-0003-2811-3579 | en_US |
dc.contributor.authorID | 0000-0002-4912-7307 | en_US |
dc.contributor.authorID | 0000-0002-4912-7307 | en_US |
dc.contributor.authorID | 0000-0002-3795-5375 | en_US |
dc.identifier.volume | 11 | en_US |
dc.relation.tubitak | info:eu-repo/grantAgreement/TUBITAK/109 O 862 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |